unknown
Stage
About
DeuterOncology is developing DO-2 (and its active metabolite DO-5), novel MET- and RAS-pathway inhibitors in the family of EGFR inhibitors, initially targeting the exon-14 skipping mutant subset (~3–4%) of non-small cell lung cancer (NSCLC) patients and planning to expand into other EGFR-driven cancers.
Explore DeuterOncology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.